Shire’s Fosrenol User Fee Date Is Oct. 26 Following 90-Day Extension
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA extends the review timeline to evaluate recently submitted dosage strength and formulation data. Shire says no clinical or safety concerns have been raised and market preparation for a late 2004 launch is proceeding as planned.